Trial Profile
Assessment of the Effects of the Specific Endothelin-A Antagonist ZD4054 on Prostate Cancer Biomarkers in Patients With Castrate-resistant Metastatic Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Zibotentan (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 21 Jul 2019 Status changed from recruiting to completed.
- 05 Aug 2010 New trial record